Drug therapy after corneal transplantation in patients with cytomegalovirus corneal endotheliitis

Authors: Zhang Xuanjun,  Hong Jing
DOI: 10.3760/cma.j.cn115989-20211231-00728
Published 2023-10-10

Cite as Chin J Exp Ophthalmol, 2023, 41(10): 1028-1032.

Abstract                            【Download PDF】 【Read Full Text

Cytomegalovirus (CMV) is a primary pathogen causing corneal endotheliitis, which may necessitate corneal transplantation if corneal transparency can not be restored.Recurrence of CMV infection and immune rejection are the main causes of graft failure, emphasizing proper postoperative drug therapy to improve the prognosis of patients.Long-term use of antiviral medications is necessary in order to prevent viral recurrence for patients suffering from CMV corneal endotheliitis who have undergone corneal transplantations.When unexplained endothelial decompensation occurs after corneal transplantation, the diagnosis and treatment of CMV endotheliitis must be emphasized.Topical use of glucocorticoids is the main means to prevent immune rejection.Due to the lower incidence of rejection and increased risk of viral recurrence, reducing or even eliminating the use of immunosuppressants may be considered for patients receiving endothelial keratoplasty.In this paper, different antiviral and anti-rejection drug regimens for patients who have undergone corneal transplantation were reviewed to find more effective and reasonable regimens and provide references for clinical treatment.

Key words:

Cytomegalovirus; Corneal endotheliitis; Corneal transplantation; Antiviral agents; Immunosuppressants

Contributor Information

Zhang Xuanjun

Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Beijing 100191, China

Hong Jing

Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Beijing 100191, China

(Read 16 times, 1 visits today)